RECK Antibody (28): sc-136270

RECK Antibody (28) is a mouse monoclonal IgG1 antibody that detects RECK in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). RECK, or reversion-inducing-cysteine-rich protein with Kazal motifs, plays a crucial role in regulating extracellular matrix dynamics by inhibiting the activity of matrix metalloproteinase-9 (MMP-9), an enzyme that facilitates tumor invasion and metastasis. By binding to MMP-9, RECK prevents its secretion and activation, thereby impeding tumor growth and spread. RECK is primarily located on the cell membrane, where RECK′s presence is vital for maintaining cellular integrity and preventing excessive proteolytic activity that can lead to cancer progression. Notably, RECK is characterized by multiple EGF-like repeats and serine-protease inhibitor-like domains, which are essential for RECK′s function and interaction with MMP-9. RECK expression is often downregulated in various tumors and oncogenically transformed cells, indicating that a loss of RECK activity is associated with malignant phenotypes. Furthermore, RECK transcriptional regulation is complex, as RECK is negatively influenced by the Sp1 family of transcription factors, which bind to specific motifs in the promoter region, particularly in cells transformed by the ras oncogene. Anti-RECK antibody (28) is an invaluable tool for researchers studying the mechanisms of tumor biology and the potential therapeutic implications of modulating RECK expression.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

RECK Antibody (28) References:

1. The potential of RECK inducers as antitumor agents for glioma.  |  Chen, Y. and Tseng, SH. 2012. Anticancer Res. 32: 2991-8. PMID: 22753763
2. A Hypothesis for the Role of RECK in Angiogenesis.  |  Gutiérrez, J., et al. 2016. Curr Vasc Pharmacol. 14: 106-15. PMID: 26463982
3. HDAC Inhibitors and RECK Modulate Endoplasmic Reticulum Stress in Tumor Cells.  |  Chen, Y., et al. 2017. Int J Mol Sci. 18: PMID: 28134767
4. Suppression of tumor metastasis by a RECK-activating small molecule.  |  Yoshida, Y., et al. 2022. Sci Rep. 12: 2319. PMID: 35149728
5. Pancreatic RECK inactivation promotes cancer formation, epithelial-mesenchymal transition, and metastasis.  |  Masuda, T., et al. 2023. J Clin Invest. 133: PMID: 37712427
6. Identification of RECK as a protective prognostic indicator and a tumor suppressor through regulation of the ERK/MAPK signaling pathway in gastric cancer.  |  Qi, F., et al. 2023. J Transl Med. 21: 766. PMID: 37904179
7. Hepatocellular RECK as a Critical Regulator of Metabolic Dysfunction-associated Steatohepatitis Development.  |  Dashek, RJ., et al. 2024. Cell Mol Gastroenterol Hepatol. 18: 101365. PMID: 38797477
8. RECK/GPR124-driven WNT signaling in pancreatic and gastric cancer cells.  |  Yu, H., et al. 2024. Cancer Sci. 115: 3013-3025. PMID: 38923741
9. A Role for Impaired RECK Activity in Metabolic Dysfunction-associated Steatotic Liver Disease.  |  Finck, BN. 2024. Cell Mol Gastroenterol Hepatol. 18: 101388. PMID: 39186948
10. RECK as a Potential Crucial Molecule for the Targeted Treatment of Sepsis.  |  Qin, Y., et al. 2025. J Inflamm Res. 18: 1787-1813. PMID: 39931174

The preferred RECK antibody is RECK Antibody (G-4): sc-373929.